ASIT biotech Mode of Action Study of gp-ASIT+™ for Grass Pollen Allergy Published in The Journal of Allergy and Clinical Immunology (JACI)¹
October 17, 2019 02:00 ET
|
ASIT Biotech
Data show how gp-ASIT+™, administered in a pre-seasonal 3-week treatment, is able to rapidly modulate the cellular response and induce production of blocking antibodies. This effect led to a...
ASIT biotech Receives GMP Certification for its Manufacturing Site in Liège, Belgium
October 07, 2019 01:00 ET
|
ASIT Biotech
BRUSSELS, Belgium, Oct. 07, 2019 (GLOBE NEWSWIRE) -- ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization...
ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy
September 26, 2019 01:00 ET
|
ASIT Biotech
The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotal gp-ASIT+™ Phase III trial and remains on track to deliver primary efficacy results in December 2019.ASIT biotech is...
Successful Pollen Season Confirms ASIT biotech On Track for Phase III Results of gp-ASIT+™ in December 2019
September 05, 2019 05:17 ET
|
ASIT Biotech
• End of pollen season reached in all sites, allowing for last subject visits according to plan• Vaccine industry veteran Beatrice De Vos, MD, to join ASIT biotech as Chief Medical Officer• New CMO to...
ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes
July 22, 2019 11:45 ET
|
ASIT Biotech
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT...
ASIT Biotech Continues its Transformation From Research to Late Stage Clinical Development
July 01, 2019 01:00 ET
|
ASIT Biotech
Company shareholders approve all motions at Extraordinary General MeetingFirm expects to raise €9-12 M to finance focused developmentJean-Paul Prieels confirmed as new member of Board of...